Pfizer needs the deal, and despite what some commenters are saying. . . it will clear Hart-Scott later this year.
Here's the WSJ on it:
. . .Seagen, which is based outside Seattle, helped pioneer a class of drugs known as antibody drug conjugates that can home in on tumors to strike them with a toxic agent.
Pfizer, of New York, has been looking for acquisitions to help it offset losses in sales expected as some top-selling drugs lose patent protection in the next several years. . . .
Now you know, and it looks like some banking contagion / uncertainty will continue to roil the broader markets this week.
And. . . I wouldn't expect the overnight Bitcoin bounce to be durable. Onward!
नमस्ते
No comments:
Post a Comment